Toxic epidermal necrolysis and Stevens-Johnson syndrome: Soluble Fas ligand involvement in the pathomechanisms of these diseases

被引:38
作者
Abe, Riichiro [1 ]
机构
[1] Hokkaido Univ, Grad Sch Med, Dept Dermatol, Kita Ku, Sapporo, Hokkaido 0608638, Japan
关键词
Apoptosis; Keratinocyte; Soluble Fas ligand; Stevens-Johnson syndrome; Toxic epidermal necrolysis;
D O I
10.1016/j.jdermsci.2008.06.003
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Toxic epidermal necrolysis (TEN) and Stevens-Johnson syndrome (SJS) are considered part of a spectrum of adverse cutaneous drug reactions showing severe and extensive skin detachment. TEN and SJS are morphologically characterized by active apoptotic keratinocyte cell death that results in the separation of the epidermis from the dermis. TEN is a life-threatening disease with a high mortality rate (20-30%). Although several therapies have been tried, there is no specific outstanding of generally accepted treatment for TEN at present. The pathogeneses of TEN and SJS have not yet been fully elucidated. We have demonstrated that high concentrations of soluble FasL (sFasL) are detected in TEN/ SJS patients' serum samples and sFasL secreted by peripheral blood mononuclear cells interacts with the Fas expressed on diseased keratinocytes in TEN/SJS. Our data suggested sFasL is a prime candidate for therapeutic intervention, whereas a few recent papers have reported sFasL levels were not elevated in some TEN patients. An urgent review of the pathophysiology in TEN/SJS is needed to resolve this issue and to determine more effective treatment regimes. (c) 2008 Japanese Society for Investigative Dermatology. Published by Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:151 / 159
页数:9
相关论文
共 49 条
[1]   Toxic epidermal necrolysis and Stevens-Johnson syndrome are induced by soluble Fas ligand [J].
Abe, R ;
Shimizu, T ;
Shibaki, A ;
Nakamura, H ;
Watanabe, H ;
Shimizu, H .
AMERICAN JOURNAL OF PATHOLOGY, 2003, 162 (05) :1515-1520
[2]   Intravenous immunoglobulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis - A prospective noncomparative study showing no benefit on mortality or progression [J].
Bachot, N ;
Revuz, J ;
Roujeau, JC .
ARCHIVES OF DERMATOLOGY, 2003, 139 (01) :33-36
[3]   Plasma exchange in patients with toxic epidermal necrolysis [J].
Bamichas, G ;
Natse, T ;
Christidou, F ;
Stangou, M ;
Karagianni, A ;
Koukourikos, S ;
Chaidemenos, G ;
Chrysomallis, F ;
Sombolos, K .
THERAPEUTIC APHERESIS, 2002, 6 (03) :225-228
[4]   SCORTEN: A severity-of-illness score for toxic epidermal necrolysis [J].
Bastuji-Garin, S ;
Fouchard, N ;
Bertocchi, M ;
Roujeau, JC ;
Revuz, J ;
Wolkenstein, P .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2000, 115 (02) :149-153
[5]   Toxic epidermal necrolysis [J].
Becker, DS .
LANCET, 1998, 351 (9113) :1417-1420
[6]   Elevated circulating CD40 ligand in patients with erythema multiforme and Stevens-Johnson syndrome/toxic epidermal necrolysis spectrum [J].
Caproni, M ;
Antiga, E ;
Parodi, A ;
Schena, D ;
Marzano, A ;
Quaglino, P ;
De Simone, C ;
La Placa, M ;
Volpi, W ;
Del Bianco, E ;
Fabbri, P .
BRITISH JOURNAL OF DERMATOLOGY, 2006, 154 (05) :1006-1007
[7]   Plasmapheresis in toxic epidermal necrolysis [J].
Chaidemenos, GC ;
Chrysomallis, F ;
Sombolos, K ;
Mourellou, O ;
Ioannides, D ;
Papakonstantinou, M .
INTERNATIONAL JOURNAL OF DERMATOLOGY, 1997, 36 (03) :218-221
[8]   Toxic epidermal necrolysis: current evidence, practical management and future directions [J].
Chave, TA ;
Mortimer, NJ ;
Sladden, MJ ;
Hall, AP ;
Hutchinson, PE .
BRITISH JOURNAL OF DERMATOLOGY, 2005, 153 (02) :241-253
[9]   INTESTINAL INVOLVEMENT IN DRUG-INDUCED TOXIC EPIDERMAL NECROLYSIS [J].
CHOSIDOW, O ;
DELCHIER, JC ;
CHAUMETTE, MT ;
WECHSLER, J ;
WOLKENSTEIN, P ;
BOURGAULT, I ;
ROUJEAU, JC ;
REVUZ, J .
LANCET, 1991, 337 (8746) :928-928
[10]   A marker for Stevens-Johnson syndrome [J].
Chung, WH ;
Hung, SI ;
Hong, HS ;
Hsih, MS ;
Yang, LC ;
Ho, HC ;
Wu, JY ;
Chen, YT .
NATURE, 2004, 428 (6982) :486-486